Skip to main content
. 2023 Jun 26;208(4):406–416. doi: 10.1164/rccm.202306-0944OC

Figure 2.


Figure 2.

(A) Kaplan-Meier plot of time to first moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation over 24 weeks in the ENHANCE-1 trial (modified intention-to-treat population [mITT]). Hazard ratio versus placebo (95% confidence interval [CI]), 0.62 (0.39, 0.97); P = 0.038. (B) Kaplan-Meier plot of time to first moderate or severe COPD exacerbation over 24 weeks in the ENHANCE-2 trial (mITT). Hazard ratio versus placebo (95% CI), 0.58 (0.38, 0.87); P = 0.009.